Novo Nordisk sues Hims after $49 weight-loss pill sparks FDA backlash (reuters.com)

Novo's stock jumped 8% on this news, and HIMS pulled their compounded weightloss pill in the face of mounting legal and regulatory pressure.

Feel like the next shoe to drop will be supply chain- going after API suppliers and the compounders.

No surprise

Their international patents expire this year, so it'll become a game of whack-a-mole trying to stop individuals from importing generics.